FDA Accepts sBLA for Pembrolizumab in Stage IB, II, or III NSCLC
June 13th 2022A new supplemental biologics license application has been accepted by the FDA for pembrolizumab as treatment of patients with 1B (≥4 centimeters), 2, or 3 non-small cell lung cancer after complete surgical resection.
Read More
KEYNOTE-799 Results Reveal Durable Responses in Previously Untreated Stage III NSCLC
June 9th 2022In patients with previously untreated, locally advanced stage III non–small cell lung cancer, continued benefit from pembrolizumab with concurrent chemoradiation followed by additional pembrolizumab was observed after more than 2 years of follow-up.
Read More
Brain Metastasis in Patients With NSCLC Correlates With Enrichment of CDKN2A/B and EGFR Mutations
June 6th 2022Correlations between non–small cell lung cancer the metastasizes to the brain and enriched CDKN2A/B and EGFR alterations calls for further genomic exploration of this patient population.
Read More
Patients with NSCLC Experience Improved DFS with Pembrolizumab After Surgery
June 6th 2022Adjuvant pembrolizumab led to improved disease-free survival versus placebo in patients with fully resected non–small cell lung cancer, according to second interim results from the PEARLS/KEYNOTE-091 trial.
Read More
Pembrolizumab With Ramucirumab Boosts Survival Vs SOC in ICI-Resistant NSCLC
June 3rd 2022The use of pembrolizumab plus ramucirumab to treat non–small cell lung cancer in immune checkpoint inhibitor resistant patients showed better overall survival versus standard of care regimens in the Lung-MAP nonmatched phase 2 substudy S1800A.
Read More
Sugemalimab Demonstrates Clinically Meaningful PFS Boost in Unresectable NSCLC
May 26th 2022GEMSTONE-301 showed sugemalimab to demonstrate a statistically significant and clinically meaningful improvement in progression-free survival in patients with unresectable stage 3 non-small cell lung cancer without disease progression after concurrent or sequential chemoradiotherapy.
Read More
Low Molecular Testing Rate, Disparities in Care Shown in Real-World Study of NSCLC in Latin America
May 24th 2022Findings from a retrospective real world study conducted in patients with EGFR-mutated, stage IV non–small cell lung cancer from 4 Latin American countries showed a 66% frequency rate in molecular testing and a frequency of EGFR mutations of 22% overall.
Read More
Oleclumab/Monalizumab With Durvalumab Improves Response and PFS Over Monotherapy in NSCLC
May 11th 2022The demonstration of clinical benefit of oleclumab or monalizumab added to durvalumab vs durvalumab alone in the COAST study support further evaluation of these combinations in the larger study.
Read More
PACIFIC-9 Starts Dosing Durvalumab With Monalizumab or Oleclumab in Patients With Unresectable NSCLC
May 4th 2022As a follow-up to the success observed in the phase 2 COAST study, investigators of the phase 3 PACIFIC-9 have begun administering durvalumab in combination with monalizumab or oleclumab to patients with unresectable, stage III non–small cell lung cancer.
Read More